CLOs on the Move

Kingsley Gate

www.kingsleygate.com

 
The executive search industry is ripe for change. True disruption needs vision and courage. It needs a firm filled with people who are not just willing to change but who want to be the very ones to leave their fingerprints on the transformation itself. Kingsley Gate Partners is a global executive search consulting firm founded with one vision in mind - to transform the world of executive search. Our partnership spans over five continents with completed searches in over 30 countries. Our mission and value proposition is simple: more Accurate, higher Velocity search by ensuring that our consultants are armed with ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Wapsie Produce

Wapsie Produce, Inc. is a Decorah, IA-based company in the Business Services sector.

Encompass Medical Transcript

Encompass Medical Transcript is a Waukesha, WI-based company in the Business Services sector.

Grayco

Grayco is a Beaufort, SC-based company in the Business Services sector.

Denali Therapeutics

Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denalis innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denalis mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.